Cipla rises on inking pact to sell 51.18% stake in Cipla Quality Chemical Industries!
The proposed sale is expected to be completed by May 31, 2023.
Cipla and its wholly-owned subsidiaries
Cipla and its wholly owned subsidiaries - Cipla (EU), UK and Meditab Holdings, Mauritius, have entered into a Share Purchase agreement with Africa Capitalworks SSA 3 on March 14, 2023, for the sale of a 51.18% stake held in Cipla Quality Chemical Industries (CQCIL), Uganda. After the sale, CQCIL will cease to be a subsidiary of the Company. The proposed sale is expected to be completed by May 31, 2023.
The consideration to be received by Cipla (EU) and Meditab Holdings shall be in the range of $25-30 million which shall be subject to annualized audited EBITDA of CQCIL for FY23 and other adjustments as agreed between the parties and stated in the Share Purchase Agreement.
Share price movement of Cipla Limited
Today, the stock opened at Rs 876.90, with a high and low of Rs 883.55 and Rs 872.90. The stock closed trading at Rs 878.15, up by 0.68%.
The stock has a 52-week high of Rs 1185.20 and a 52-week low of Rs 853.50. The company has a ROCE of 15.7% with a market capitalisation of Rs 70,879 crore.
Cipla Limited is a global pharmaceutical company focused on the responsible and sustainable growth of complex generics and deepening its portfolio in home markets of India, South Africa and North America, as well as key regulated and emerging markets. The company is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company has a wide network of manufacturing, trading and other incidental operations in India and International markets.
Share Market Today
|Indices Name||Price||Price Change (% change)|
|S&P ASX 200||6914.00||0.1 (0%)|
|CAC 40||6997.05||-71.11 (-1.01%)|
|Dow Jones||33002.38||-430.97 (-1.29%)|
|FTSE 100||7470.16||-40.56 (-0.54%)|
|Hang Seng||17298.46||-524.12 (-2.94%)|
|US Tech 100||13064.47||-248.3 (-1.87%)|
|Nikkei 225||31237.94||-521.94 (-1.64%)|
|S&P 500||4229.45||-58.94 (-1.37%)|
|Gift Nifty||19450.50||-163 (-0.83%)|
|Shanghai Composite||3110.48||0 (0%)|
|Taiwan Weighted||16454.34||-102.97 (-0.62%)|
|US 30||33001.80||-2 (-0.01%)|
About the Author
DisclaimerInvestment/Trading in securities Market is subject to market risk, past performance is not a guarantee of future performance. The risk of loss in trading and investment in Securities markets including Equites and Derivatives can be substantial.
Bombay Stock Exchange (BSE) has announced the discontinuation of Stop Loss Market (SL-M) orders, effective from October 9. This decision follows a recent incident involving a "freak trade" triggered by an SL-M order, which led to concerns within the trading community. The aim is to prevent erroneous order placements, whether they result from manual or algorithmic trading.
- Oct 03, 2023
Valiant Laboratories Ltd has a face value of ₹10 per share while the price band for the book building IPO has been set in the band of ₹133 to ₹140 per share. The final price will be discovered within this band, through the process of book building. The fresh issue portion entailed the issue of 1,08,90,000 shares (108.90 lakh shares), which at the upper price band of ₹140 per share will translate into fresh issue size of ₹152.46 crore.
- Oct 03, 2023
Premium listing for Saakshi Medtech and Panels Ltd, then hits upper circuit Saakshi Medtech and Panels Ltd had a strong listing on 03rd October 2023, listing at a premium of 50.52%, and subsequently hitting the 5% upper circuit on
- Oct 03, 2023